POINT
Multicenter, randomized, double-blind, parallel-group, add-on, superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera®)
What was tested
Treatment tested
- Ponesimod
Sphingosine 1-phosphate receptor Edg-1 agonist
What it measured
Main measures
Annualized relapse rate (ARR); defined as the number of confirmed relapses per subject-year.
Relapses
Other measures (1)
1. Time to 12-week confirmed disability accumulation (CDA)
Disability progression
Papers
Loading reviews and guidelines…
Related trials
- VOYAGE
Phase 3 · Not yet recruiting
Still running
- TG1101-RMS-PED304
Phase 2 / Phase 3 · Recruiting
Still running
- IM047-050
Phase 3 · Recruiting
Still running
- COAST
Phase 4 · Recruiting
Still running
- Assessing the Cognitive Benefits of Ozanimod and Their Br…
Phase 4 · Withdrawn
Stopped early
- A Study to Assess the Effectiveness and Safety of Ozanimo…
Phase 4 · Running, not recruiting
Still running
History
- In scope changed from true to false
Started
Jul 2016
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error